India, July 13 -- Q32 Bio Inc. (QTTB) shares surged $9.30, or 83.01 percent, to $20.51 on Monday, after the clinical-stage biotechnology company reported positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial evaluating bempikibart in patients with severe or very severe alopecia areata.
The stock opened at $18.33 after closing at $11.21 in the previous session on the Nasdaq. It traded between $17.28 and $20.74 during the session, with 17.74 million shares changing hands, compared with an average daily volume of 0.81 million shares. The stock has traded between $1.57 and $20.74 over the past 52 weeks.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The study met its primary effica...